GLD

GLD Partners LP is a Los Angeles-based investment firm that has transitioned into a direct drug development and healthcare operations entity. In late 2025, the company significantly expanded its life sciences footprint by acquiring the late-stage clinical pipeline of Seelos Therapeutics, including intranasal ketamine (SLS-002) and trehalose (SLS-005), both of which are advancing into Phase 3 trials for CNS and rare neurodegenerative disorders. Additionally, GLD launched Altagenics, a biotechnology subsidiary focused on muscle-wasting conditions such as sarcopenia and cachexia, utilizing the proprietary GigaAssay functional genomics platform. The firm also operates Orion Specialty Labs, a 503B outsourcing facility, and Polomar Health Services, providing a vertically integrated model for pharmaceutical innovation and commercialization.